Literature DB >> 16150516

Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device.

Henry Hebel1, Heather Attra, Amir Khan, Ruxandra Draghia-Akli.   

Abstract

We have developed three major technologies that allow plasmid-based products to be used for large-scale vaccination or therapeutic protein applications. Our team has integrated these components into one complete, cost-effective, easy-to-use system capable of rapid implementation under field conditions. The proprietary manufacturing process uses a lysis method and membrane-based chromatography to rapidly produce large-scale batches of plasmid. Plasmid doses are filled into the Becton-Dickinson Uniject container/closure system. The Uniject adapts to the electrode array of our constant current electrokinetic device, such that the plasmid is delivered in the area of tissue defined by the electrodes. Thus, plasmid uptake and expression levels are dramatically improved. This is the first completely integrated delivery system for plasmid-based products.

Mesh:

Year:  2005        PMID: 16150516     DOI: 10.1016/j.vaccine.2005.08.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.

Authors:  Lauren A Hirao; Ruxandra Draghia-Akli; Jonathan T Prigge; Maria Yang; Abhishek Satishchandran; Ling Wu; Erika Hammarlund; Amir S Khan; Tahar Babas; Lowrey Rhodes; Peter Silvera; Mark Slifka; Niranjan Y Sardesai; David B Weiner
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.

Authors:  Ralph LeBlanc; Yessika Vasquez; Drew Hannaman; Nirbhay Kumar
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

3.  Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Authors:  Jukka Hartikka; Vesselina Bozoukova; Jane Morrow; Denis Rusalov; Mark Shlapobersky; Qun Wei; Sou Boutsaboualoy; Ming Ye; Mary K Wloch; John Doukas; Sean Sullivan; Alain Rolland; Larry R Smith
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

4.  Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process.

Authors:  Jared Nelson; Stephen Rodriguez; Neil Finlayson; Jim Williams; Aaron Carnes
Journal:  Hum Vaccin Immunother       Date:  2013-07-30       Impact factor: 3.452

5.  Adiponectin gene therapy ameliorates high-fat, high-sucrose diet-induced metabolic perturbations in mice.

Authors:  A D Kandasamy; M M Sung; J J Boisvenue; A J Barr; J R B Dyck
Journal:  Nutr Diabetes       Date:  2012-09-10       Impact factor: 5.097

6.  Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

Authors:  Dominick J Laddy; Jian Yan; Michele Kutzler; Darwyn Kobasa; Gary P Kobinger; Amir S Khan; Jack Greenhouse; Niranjan Y Sardesai; Ruxandra Draghia-Akli; David B Weiner
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.